Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. (Q39608458)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Shampa Das

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Gary K Schwartz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Richard D Carvajal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Rachel Midgley

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Scott J Rodig

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Ozlem Ataman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

David Wilson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Geoffrey I Shapiro

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

2 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

370-380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

The cellular geography of aurora kinases

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora kinases in spindle assembly and chromosome segregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Chromosomal passengers: conducting cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora kinases: shining lights on the therapeutic horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora kinases: new targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Mitotic drivers--inhibitors of the Aurora B Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora kinases as anticancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora kinase inhibitors: identification and preclinical validation of their biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Clinical experience with aurora kinase inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9825-7

Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22661287

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-012-9825-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22661287%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference